New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.

Read More

7 Crucial Facts About Medical Cannabis Safety for 2024

Medical cannabis is showing promise in treating a variety of symptoms without compromising cognitive health, but understanding its long-term safety is key. A recent study reveals that light to moderate use of cannabis may not impair cognition over one year, but issues like tolerance and dose escalation remain concerns for the future.

Read More